Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Mitchell

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Bulletin of the New York Academy of Medicine|January 1, 1989
Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanomaM S Mitchell, R A Kempf, W Harel, et al.
Cancer Investigation|January 1, 1994
Case report: clinical findings and successful resection of melanoma metastatic to the right atriumD M Merer, J P Dutcher, A Mercando, et al.
Connecticut Medicine|December 1, 1970
The Yale combination chemotherapy program for advanced Hodgkin's disease. A preliminary reportM Levitt, R C DeConti, H A Pearson, et al.
American Journal of Clinical Oncology|April 1, 1996
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921)L E Flaherty, P Y Liu, M S Mitchell, et al.
Hybridoma|April 1, 1989
Monoclonal antibody L/1C2 reactive with a human carcinoma associated antigenD A Johnson, M C Gutowski, E K Berger, et al.
Cancer Research|January 1, 1985
Cytotoxic activity of human pulmonary alveolar macrophagesJ Kan-Mitchell, J C Hengst, R A Kempf, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1993
Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapyJ Kan-Mitchell, X Q Huang, L Steinman, et al.
Gut|April 16, 2002
The changing scope of colorectal cancerJ S White, K Mc Callion, K R Gardiner, et al.
Diabetes|April 30, 2003
Genetic variation in the small heterodimer partner gene and young-onset type 2 diabetes, obesity, and birth weight in U.K. subjectsSimon M S Mitchell, Michael N Weedon, Katharine R Owen, et al.
Journal of Biological Response Modifiers|February 1, 1986
Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinomaR A Kempf, S M Grunberg, J R Daniels, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Bulletin of the New York Academy of Medicine|January 1, 1989
Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanomaM S Mitchell, R A Kempf, W Harel, et al.
Cancer Investigation|January 1, 1994
Case report: clinical findings and successful resection of melanoma metastatic to the right atriumD M Merer, J P Dutcher, A Mercando, et al.
Connecticut Medicine|December 1, 1970
The Yale combination chemotherapy program for advanced Hodgkin's disease. A preliminary reportM Levitt, R C DeConti, H A Pearson, et al.
American Journal of Clinical Oncology|April 1, 1996
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921)L E Flaherty, P Y Liu, M S Mitchell, et al.
Hybridoma|April 1, 1989
Monoclonal antibody L/1C2 reactive with a human carcinoma associated antigenD A Johnson, M C Gutowski, E K Berger, et al.
Cancer Research|January 1, 1985
Cytotoxic activity of human pulmonary alveolar macrophagesJ Kan-Mitchell, J C Hengst, R A Kempf, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1993
Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapyJ Kan-Mitchell, X Q Huang, L Steinman, et al.
Gut|April 16, 2002
The changing scope of colorectal cancerJ S White, K Mc Callion, K R Gardiner, et al.
Diabetes|April 30, 2003
Genetic variation in the small heterodimer partner gene and young-onset type 2 diabetes, obesity, and birth weight in U.K. subjectsSimon M S Mitchell, Michael N Weedon, Katharine R Owen, et al.
Journal of Biological Response Modifiers|February 1, 1986
Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinomaR A Kempf, S M Grunberg, J R Daniels, et al.
Pageof 18